Curative Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Indication, By End User, By Region and Competition, 2020-2030F

Description

The Global Curative Therapeutics Market will grow from USD 485.21 Million in 2024 to USD 762.72 Million by 2030 at a 7.83% CAGR. Curative therapeutics encompass advanced medical interventions engineered to permanently resolve diseases by targeting and correcting their fundamental causes, moving beyond conventional symptomatic management. The market's expansion is primarily driven by the substantial global burden of chronic and rare diseases, coupled with continuous advancements in biotechnological platforms such as gene editing and cell therapies, and increasing investments in research and development accelerating the pipeline of novel candidates.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 485.21 Million
Market Size 2030	USD 762.72 Million
CAGR 2025-2030	7.83%
Fastest Growing Segment	Cancer
Largest Market	North America

Key Market Drivers

Breakthroughs in cell and gene therapy represent a paramount driver for the global curative therapeutics market, fundamentally reshaping treatment paradigms for previously intractable diseases. These advanced modalities offer potential for one-time cures by correcting underlying genetic defects or harnessing the body's immune system to combat illness. The accelerating pace of innovation, evidenced by novel therapeutic approvals, signifies platform maturation. According to RegMedNet, in May 2025, "FDA-Approved Cell and Gene Therapies", the US Food and Drug Administration approved nine cell and gene therapy products in 2024, targeting conditions such as cancer, hemophilia B, and aromatic L-amino acid decarboxylase deficiency. This demonstrates expanding regulatory confidence and the broader scope of conditions amenable to these revolutionary approaches.

Key Market Challenges

A significant challenge impeding the expansion of the Global Curative Therapeutics Market is the high upfront cost associated with developing and delivering these complex therapies. This factor directly creates affordability concerns for healthcare systems and patients, consequently limiting widespread access and consistent reimbursement for treatments, even those demonstrating high efficacy. Such substantial costs strain national healthcare budgets and individual patient finances, thereby hindering the broader adoption necessary for robust market growth.

Key Market Trends

Increased Payer Acceptance of Value-Based Pricing for Curative Therapies is significantly influencing the global curative therapeutics market by providing new frameworks for drug reimbursement. This trend addresses the substantial upfront costs of these advanced treatments by linking payment to predefined clinical outcomes or long-term efficacy, thereby reducing financial risk for healthcare systems and fostering greater market access. This approach encourages a shift from volume-based to value-based healthcare, where the economic burden is shared, and therapies are evaluated on their demonstrated patient benefit.

Key Market Players

Pfizer, Inc.
GlaxoSmithKline plc
Sanofi S.A.
Bluebird bio, Inc.
Novartis AG
Spark Therapeutics, Inc.
Gilead Sciences, Inc.
Sarepta Therapeutics, Inc.
Vertex Pharmaceuticals Incorporated
Alnylam Pharmaceuticals, Inc.

Report Scope:

In this report, the Global Curative Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Curative Therapeutics Market, By Type:

Biology Modifying Drugs
Gene Therapies
Cell Therapies

Curative Therapeutics Market, By Indication:

Cancer
Musculoskeletal Disorders
Neurodegenerative Diseases
Rare Diseases
Hepatitis C
Others

Curative Therapeutics Market, By End User:

Pharmaceutical Companies
Academic & Research Institutions
Others

Curative Therapeutics Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Curative Therapeutics Market.

Available Customizations:

Global Curative Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Curative Therapeutics Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type (Biology Modifying Drugs, Gene Therapies, Cell Therapies)
- 5.2.2. By Indication (Cancer, Musculoskeletal Disorders, Neurodegenerative Diseases, Rare Diseases, Hepatitis C, Others)
- 5.2.3. By End User (Pharmaceutical Companies, Academic & Research Institutions, Others)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
5.3. Market Map

6. North America Curative Therapeutics Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Indication
- 6.2.3. By End User
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Curative Therapeutics Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type
    - 6.3.1.2.2. By Indication
    - 6.3.1.2.3. By End User
- 6.3.2. Canada Curative Therapeutics Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type
    - 6.3.2.2.2. By Indication
    - 6.3.2.2.3. By End User
- 6.3.3. Mexico Curative Therapeutics Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type
    - 6.3.3.2.2. By Indication
    - 6.3.3.2.3. By End User

7. Europe Curative Therapeutics Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Indication
- 7.2.3. By End User
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Curative Therapeutics Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By Indication
    - 7.3.1.2.3. By End User
- 7.3.2. France Curative Therapeutics Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By Indication
    - 7.3.2.2.3. By End User
- 7.3.3. United Kingdom Curative Therapeutics Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By Indication
    - 7.3.3.2.3. By End User
- 7.3.4. Italy Curative Therapeutics Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type
    - 7.3.4.2.2. By Indication
    - 7.3.4.2.3. By End User
- 7.3.5. Spain Curative Therapeutics Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type
    - 7.3.5.2.2. By Indication
    - 7.3.5.2.3. By End User

8. Asia Pacific Curative Therapeutics Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Indication
- 8.2.3. By End User
- 8.2.4. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Curative Therapeutics Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By Indication
    - 8.3.1.2.3. By End User
- 8.3.2. India Curative Therapeutics Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By Indication
    - 8.3.2.2.3. By End User
- 8.3.3. Japan Curative Therapeutics Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By Indication
    - 8.3.3.2.3. By End User
- 8.3.4. South Korea Curative Therapeutics Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Type
    - 8.3.4.2.2. By Indication
    - 8.3.4.2.3. By End User
- 8.3.5. Australia Curative Therapeutics Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By Indication
    - 8.3.5.2.3. By End User

9. Middle East & Africa Curative Therapeutics Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Indication
- 9.2.3. By End User
- 9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Curative Therapeutics Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By Indication
    - 9.3.1.2.3. By End User
- 9.3.2. UAE Curative Therapeutics Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By Indication
    - 9.3.2.2.3. By End User
- 9.3.3. South Africa Curative Therapeutics Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By Indication
    - 9.3.3.2.3. By End User

10. South America Curative Therapeutics Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By Indication
- 10.2.3. By End User
- 10.2.4. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Curative Therapeutics Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type
    - 10.3.1.2.2. By Indication
    - 10.3.1.2.3. By End User
- 10.3.2. Colombia Curative Therapeutics Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By Indication
    - 10.3.2.2.3. By End User
- 10.3.3. Argentina Curative Therapeutics Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By Indication
    - 10.3.3.2.3. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Curative Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Pfizer, Inc.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. GlaxoSmithKline plc
15.3. Sanofi S.A.
15.4. Bluebird bio, Inc.
15.5. Novartis AG
15.6. Spark Therapeutics, Inc.
15.7. Gilead Sciences, Inc.
15.8. Sarepta Therapeutics, Inc.
15.9. Vertex Pharmaceuticals Incorporated
15.10. Alnylam Pharmaceuticals, Inc.